Patents by Inventor Keunok Jung

Keunok Jung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210403580
    Abstract: An antibody or antigen-binding fragment thereof, which binds with a high pM-level affinity to a human IL-4 receptor alpha chain that is a human IL-4 receptor, is provided. The antibody or antigen-binding fragment has a different epitope and a different antigen dissociation rate than existing antibodies. A nucleic acid encoding the antibody or antigen-binding fragment thereof, a vector including the nucleic acid, a cell transformed with the vector, a method for producing the antibody or antigen-binding fragment thereof, a conjugate comprising the antibody or antigen-binding fragment thereof, a composition for preventing or treating inflammatory diseases, and a composition for diagnosing inflammatory diseases are disclosed.
    Type: Application
    Filed: November 7, 2019
    Publication date: December 30, 2021
    Applicant: Ajou University Industry-Academic Cooperation Foundation
    Inventors: Yong Sung KIM, Hae-Sim PARK, Jung Eun KIM, Keunok JUNG
  • Patent number: 11078249
    Abstract: The present invention relates to a heterodimeric Fc-fused protein comprising a first Fc region and a second Fc region of an immunoglobulin Fc pair and a physiologically active protein composed of two or more different subunits, wherein one or more subunits of the physiologically active protein are linked separately to one or more ends of the N-terminus or C-terminus of the first Fc region and/or the second Fc region, and CH3 domains of the first Fc region and the second Fc region are mutated so as to promote the heterodimeric Fc formation. Moreover, the present invention relates to a pharmaceutical composition comprising the heterodimeric Fc-fused protein.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: August 3, 2021
    Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Yong Sung Kim, Keunok Jung, Ji Hee Ha, Dong Ki Choi, Hye Ji Choi, Ye Jin Kim
  • Publication number: 20200362005
    Abstract: The present invention relates to a heterodimeric Fc-fused protein comprising a first Fc region and a second Fc region of an immunoglobulin Fc pair and a physiologically active protein composed of two or more different subunits, wherein one or more subunits of the physiologically active protein are linked separately to one or more ends of the N-terminus or C-terminus of the first Fc region and/or the second Fc region, and CH3 domains of the first Fc region and the second Fc region are mutated so as to promote the heterodimeric Fc formation. Moreover, the present invention relates to a pharmaceutical composition comprising the heterodimeric Fc-fused protein.
    Type: Application
    Filed: May 28, 2020
    Publication date: November 19, 2020
    Inventors: Yong Sung Kim, Keunok Jung, Ji Hee Ha, Dong Ki Choi, Hye Ji Choi, Ye Jin Kim
  • Publication number: 20200362004
    Abstract: The present invention relates to a heterodimeric Fc-fused protein comprising a first Fc region and a second Fc region of an immunoglobulin Fc pair and a physiologically active protein composed of two or more different subunits, wherein one or more subunits of the physiologically active protein are linked separately to one or more ends of the N-terminus or C-terminus of the first Fc region and/or the second Fc region, and CH3 domains of the first Fc region and the second Fc region are mutated so as to promote the heterodimeric Fc formation. Moreover, the present invention relates to a pharmaceutical composition comprising the heterodimeric Fc-fused protein.
    Type: Application
    Filed: May 28, 2020
    Publication date: November 19, 2020
    Inventors: Yong Sung Kim, Keunok Jung, Ji Hee Ha, Dong Ki Choi, Hye Ji Choi, Ye Jin Kim
  • Publication number: 20200276328
    Abstract: The present invention relates to a composition for inhibiting regulatory T cell immunosuppression, containing a fusion protein comprising a peptide that binds specifically to neuropilin 1 (NRP1). The fusion protein comprising the peptide that binds specifically to neuropilin 1 according to the present invention can reduce the proportion of regulatory T cells among CD4+ T cells in tumor tissue and inhibit the activity of regulatory T cells that infiltrated into tumor tissue, thereby down-regulating immunosuppression in the tumor tissue without causing systemic toxicity. Thus, the fusion protein can exhibit a high effect on tumor treatment.
    Type: Application
    Filed: September 7, 2018
    Publication date: September 3, 2020
    Inventors: Yong Sung Kim, Ye Jin Kim, Keunok Jung, Jeong-Ah Kim
  • Patent number: 10696722
    Abstract: The present invention relates to a heterodimeric Fc-fused protein comprising a first Fc region and a second Fc region of an immunoglobulin Fc pair and a physiologically active protein composed of two or more different subunits, wherein one or more subunits of the physiologically active protein are linked separately to one or more ends of the N-terminus or C-terminus of the first Fc region and/or the second Fc region, and CH3 domains of the first Fc region and the second Fc region are mutated so as to promote the heterodimeric Fc formation. Moreover, the present invention relates to a pharmaceutical composition comprising the heterodimeric Fc-fused protein.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: June 30, 2020
    Assignee: Ajou University Industry-Academic Cooperation Foundation
    Inventors: Yong Sung Kim, Keunok Jung, Ji Hee Ha, Dong Ki Choi, Hye Ji Choi, Ye Jin Kim
  • Publication number: 20190169252
    Abstract: The present invention relates to a heterodimeric Fc-fused protein comprising a first Fc region and a second Fc region of an immunoglobulin Fc pair and a physiologically active protein composed of two or more different subunits, wherein one or more subunits of the physiologically active protein are linked separately to one or more ends of the N-terminus or C-terminus of the first Fc region and/or the second Fc region, and CH3 domains of the first Fc region and the second Fc region are mutated so as to promote the heterodimeric Fc formation. Moreover, the present invention relates to a pharmaceutical composition comprising the heterodimeric Fc-fused protein.
    Type: Application
    Filed: August 10, 2017
    Publication date: June 6, 2019
    Inventors: Yong Sung Kim, Keunok Jung, Ji Hee Ha, Dong Ki Choi, Hye Ji Choi, Ye Jin Kim